Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia
- PMID: 16813742
- DOI: 10.1016/j.ajog.2005.07.049
Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia
Abstract
Intrauterine growth restriction (IUGR) and preeclampsia differ in their association with maternal disease but share a similar placental pathology. Moreover, mothers who have had pregnancies complicated by preeclampsia or IUGR are at elevated later-life cardiovascular risk. Why, then, do some women develop IUGR and others develop preeclampsia? In this clinical opinion, based on a review of the literature, we hypothesize that both women experiencing preeclampsia and IUGR enter pregnancy with some degree of endothelial dysfunction, a lesion that predisposes to shallow placentation. In our opinion, preeclampsia develops when abnormal placentation, through the mediator of elevated circulating cytokines, interacts with maternal metabolic syndrome, comprised of adiposity, insulin resistance/hyperglycemia, hyperlipidemia, and coagulopathy. IUGR develops in the absence of antenatal metabolic syndrome. Among these women, the baby is affected by shallow placentation but the mother does not develop clinically apparent disease. This conceptualization provides a testable framework for future etiologic studies of preeclampsia and IUGR.
Similar articles
-
Myeloperoxidase in the plasma and placenta of normal pregnant women and women with pregnancies complicated by preeclampsia and intrauterine growth restriction.Placenta. 2012 Apr;33(4):294-303. doi: 10.1016/j.placenta.2012.01.004. Epub 2012 Jan 20. Placenta. 2012. PMID: 22264587
-
PTX3 as a potential endothelial dysfunction biomarker for severity of preeclampsia and IUGR.Placenta. 2012 Dec;33(12):1039-44. doi: 10.1016/j.placenta.2012.09.009. Epub 2012 Oct 9. Placenta. 2012. PMID: 23062219
-
Risk factors for cardiovascular disease in women with a history of pregnancy complicated by preeclampsia or intrauterine growth restriction.Hypertens Pregnancy. 2007;26(1):39-50. doi: 10.1080/10641950601146574. Hypertens Pregnancy. 2007. PMID: 17454217
-
Pre-eclampsia: fitting together the placental, immune and cardiovascular pieces.J Pathol. 2010 Aug;221(4):363-78. doi: 10.1002/path.2719. J Pathol. 2010. PMID: 20593492 Review.
-
Endovascular trophoblast invasion: implications for the pathogenesis of intrauterine growth retardation and preeclampsia.Biol Reprod. 2003 Jul;69(1):1-7. doi: 10.1095/biolreprod.102.014977. Epub 2003 Mar 5. Biol Reprod. 2003. PMID: 12620937 Review.
Cited by
-
Chromogranin A: its known and possible roles in obstetrics and gynecology.Dev Period Med. 2018;22(4):297-300. doi: 10.34763/devperiodmed.20182204.297300. Dev Period Med. 2018. PMID: 30636225 Free PMC article.
-
Placental pathology in pregnancies complicated by fetal growth restriction: recurrence vs. new onset.Arch Gynecol Obstet. 2020 Jun;301(6):1397-1404. doi: 10.1007/s00404-020-05546-x. Epub 2020 Apr 24. Arch Gynecol Obstet. 2020. PMID: 32333099
-
Uterine Regulatory T cells, IL-10 and hypertension.Am J Reprod Immunol. 2011 Jul;66 Suppl 1(Suppl 1):88-92. doi: 10.1111/j.1600-0897.2011.01040.x. Am J Reprod Immunol. 2011. PMID: 21726343 Free PMC article. Review.
-
Lipid profiling in maternal and fetal circulations in preeclampsia and fetal growth restriction-a prospective case control observational study.BMC Pregnancy Childbirth. 2020 Jan 30;20(1):61. doi: 10.1186/s12884-020-2753-1. BMC Pregnancy Childbirth. 2020. PMID: 32000699 Free PMC article.
-
Protective effect of nuclear factor E2-related factor 2 on inflammatory cytokine response to brominated diphenyl ether-47 in the HTR-8/SVneo human first trimester extravillous trophoblast cell line.Toxicol Appl Pharmacol. 2014 Nov 15;281(1):67-77. doi: 10.1016/j.taap.2014.09.015. Epub 2014 Oct 11. Toxicol Appl Pharmacol. 2014. PMID: 25305463 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical